A Vaccine (PDS0101) Alone or in Combination with Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

PDS0101 is a novel, investigational HPV-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers utilizing a mixture of HPV16 E6 and E7 peptides pools delivered subcutaneously with cationic (positively charged) lipid nanoparticles. Initial studies of PDS0101 in combination with pembrolizumab in patients with metastatic HPV16-positive recurrent/metastatic HNSCC demonstrated clinical activity with notable polyfunctional HPV16-specific CD4 and CD8 T cell activation.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: D.M. Routman, K. Van Abel, K. Bartemes, N.R. Foster, N. Riebel, L. Wood, A.A. Nagelschneider, J.J. Garcia, A.V. Chintakuntlawar, K. Price Tags: 116 Source Type: research